Cargando…
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The result of more than thirty years of research, anti-CGRP monoclonal antibodies are currently the state of the art for migraine preventive therapy. Their efficacy and safety, supported by an already large and growing body of evidence, are added by many other advantages: an early onset of action, f...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491437/ https://www.ncbi.nlm.nih.gov/pubmed/35976302 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S112 |